Picture of Polarean Imaging logo

POLX Polarean Imaging News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

RCS - Polarean Imaging PLC - System delivery

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220708:nRSH7366Ra&default-theme=true

RNS Number : 7366R  Polarean Imaging PLC  08 July 2022

Polarean Imaging Plc

("Polarean" or the "Company")

 

System delivery

 

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company,
with an investigational drug‑device combination product using hyperpolarised
(129)Xenon gas to enhance magnetic resonance imaging (MRI) in pulmonary
medicine, announces that following on from the RNS on 25 April 2022, it has
completed the installation of the additional Xenon Polariser 9820 at the
Center for Pulmonary Imaging Research at the Cincinnati Children's Hospital
Medical Center ("CCHMC").

 

CCHMC is a non-profit academic medical center, which is distinguished and
globally renowned for paediatric teaching and research, and is one of the
Company's longest key clinical research collaborators. A key focus of the
collaboration is to lead the field of paediatric pulmonary imaging through
advanced imaging techniques and lung function imaging, including
hyperpolarised (129)Xenon gas.

 

Richard Hullihen, CEO of Polarean Imaging said: "CCHMC runs an exceptional
programme for advancing non-invasive hyperpolarised noble gas MR imaging in
paediatric research and we are thrilled that we can support them in their
endeavours. The CCHMC have made significant progress in their research efforts
in early detection, diagnostic development, evaluation and management of
serious lung diseases and we believe our partnership can help them improve the
outcomes for these most vulnerable of patients."

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                          (http://www.polarean-ir.com)
 Richard Hullihen, Chief Executive Officer                Via Walbrook PR
 Kenneth West, Chairman

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                 +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / William Palmer-Brown (Healthcare
 Investment Banking)
 Nick Adams / Fred Walsh / Nick Harland (Corporate Broking)

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy /Phillip Marriage         Mob: +44 (0)7879 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue-generating, investigational drug-device combination
companies operating in the high-resolution medical imaging research space.

 

The Group develops equipment that enables existing MRI systems to achieve an
improved level of pulmonary function imaging and specialises in the use of
hyperpolarised Xenon gas ((129)Xe) as an imaging agent to visualise
ventilation. (129)Xe gas is currently being studied for visualisation of gas
exchange regionally in the smallest airways of the lungs, across the alveolar
tissue membrane, and into the pulmonary bloodstream.

 

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA
for hyperpolarised (129)Xe used to evaluate pulmonary function and to
visualise the lung using MRI. The Group received a complete response letter on
5 October 2021. On 30 March 2022, the Company filed the resubmission of its
NDA with the US FDA and has received a PDUFA date of Sept 30, 2022.

 

The Group operates in an area of significant unmet medical need and the
Group's technology provides a novel investigational diagnostic approach,
offering a non-invasive and radiation-free functional imaging platform.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZDLFBLDLXBBB

Recent news on Polarean Imaging

See all news